One of the most significant challenges facing the Bio-Pharm industry in recent years has been how to reduce development timelines and cost; billons of dollars have been invested in this area, with significant success. This has included the adoption of high throughput screening technologies, rapid single stage scale up of manufacturing process and, not least, the widespread adoption of single use technologies in development and manufacturing facilities for the production on antibody based produ...
